Natera, Inc. (NASDAQ:NTRA) Insider Jonathan Sheena Sells 447 Shares of Stock

Natera, Inc. (NASDAQ:NTRAGet Free Report) insider Jonathan Sheena sold 447 shares of the business’s stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $90.22, for a total transaction of $40,328.34. Following the completion of the transaction, the insider now owns 347,731 shares of the company’s stock, valued at $31,372,290.82. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jonathan Sheena also recently made the following trade(s):

  • On Tuesday, March 5th, Jonathan Sheena sold 1,028 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $90,834.08.
  • On Tuesday, February 6th, Jonathan Sheena sold 6,000 shares of Natera stock. The shares were sold at an average price of $70.00, for a total transaction of $420,000.00.
  • On Monday, January 22nd, Jonathan Sheena sold 351 shares of Natera stock. The shares were sold at an average price of $68.16, for a total transaction of $23,924.16.
  • On Wednesday, January 3rd, Jonathan Sheena sold 5,000 shares of Natera stock. The shares were sold at an average price of $60.30, for a total transaction of $301,500.00.

Natera Stock Performance

NASDAQ:NTRA opened at $91.46 on Friday. The firm has a market capitalization of $11.04 billion, a PE ratio of -24.13 and a beta of 1.39. The business’s fifty day moving average price is $78.46 and its 200 day moving average price is $61.25. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $96.24.

Natera (NASDAQ:NTRAGet Free Report) last announced its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.09. The business had revenue of $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. On average, sell-side analysts anticipate that Natera, Inc. will post -2.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. TD Cowen increased their target price on shares of Natera from $82.00 to $87.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 12th. Piper Sandler raised their price objective on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research note on Wednesday, March 6th. Stephens reissued an “overweight” rating and issued a $78.00 price objective on shares of Natera in a research note on Tuesday, January 30th. Wolfe Research began coverage on shares of Natera in a research note on Wednesday, December 13th. They issued an “outperform” rating and a $70.00 price objective for the company. Finally, BTIG Research raised their price objective on shares of Natera from $75.00 to $85.00 and gave the company a “buy” rating in a research note on Friday, December 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $78.36.

Check Out Our Latest Analysis on Natera

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently modified their holdings of NTRA. Crossmark Global Holdings Inc. increased its stake in shares of Natera by 2.2% during the 4th quarter. Crossmark Global Holdings Inc. now owns 7,267 shares of the medical research company’s stock worth $456,000 after purchasing an additional 155 shares in the last quarter. Fifth Third Bancorp grew its stake in Natera by 3.0% in the 4th quarter. Fifth Third Bancorp now owns 6,216 shares of the medical research company’s stock worth $389,000 after acquiring an additional 179 shares during the period. Treasurer of the State of North Carolina grew its stake in shares of Natera by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 45,469 shares of the medical research company’s stock valued at $2,012,000 after buying an additional 230 shares during the period. Royal Bank of Canada grew its stake in shares of Natera by 0.3% during the 3rd quarter. Royal Bank of Canada now owns 83,843 shares of the medical research company’s stock valued at $3,710,000 after buying an additional 245 shares during the period. Finally, Xponance Inc. grew its stake in shares of Natera by 1.8% during the 3rd quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock valued at $642,000 after buying an additional 261 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

About Natera

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Read More

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.